EVALUation of National Implementation of the ISARIC 4C Mortality Score in United Kingdom hospitals
Project status: Completed
Online pre-print manuscript: https://www.medrxiv.org/content/10.1101/2021.12.18.21268003v2
This was a national project aiming to gain a greater understanding of the use of the 4C mortality score in UK hospitals.
The study comprised two parts:
Part 1: An observational, cross-sectional study involved collection of basic information on the existing COVID-19 guidance/protocol at your hospital.
Part 2: A retrospective cohort study to investigate whether or not the 4C mortality score was documented in the case notes of patients presenting to hospital with COVID-19 from 11th to 24thJanuary 2021.
Investigators who submitted part 1 alone were eligible for a certificate of audit participation. Investigators who submitted both parts 1 and 2 were eligible for citable authorship as per NITCAR’s authorship policy.
The study protocol is available here.
The 4C mortality score (ISARIC 4C consortium) has been demonstrated to be a highly effective tool to assess in-hospital mortality risk in COVID-19 patients. Based on eight easy-to-access variables that include patient characteristics, physiological and blood parameters on admission, the 4C score outperformed 15 pre-existing prognostic scores in predicting mortality risk in patients with COVID- 19(1).
Anecdotal evidence suggests that hospitals have started to incorporate the 4C mortality score into their COVID-19 guidance, but no studies have assessed this.
In our study, we were collecting information about how the 4C mortality score has been incorporated into hospital COVID-19 guidance. We were also investigating whether or not the 4C mortality score was documented in patients’ case notes during the January 2021 wave of COVID-19.
No previous studies had explored the use of COVID-19 specific guidance or the application of 4C Score in the assessment of COVID-19 patients. We hope to use this information to provide clinicians with key insights into the use of the 4C score ahead of future waves of COVID-19.
Any infection doctor or junior doctor currently working in the UK with an interest in infection specialties was invited to contribute.
Summary of findings
Email us at email@example.com.
Trainee Leads: Dr Andrew Blunsum, Dr Jonathan Perkins
Principal investigator: Dr Antonia Ho